Core Insights - Silexion Therapeutics Corp. has made significant advancements in its preclinical program for SIL204, demonstrating strong efficacy across multiple KRAS-driven cancer types, including pancreatic, colorectal, and lung cancers [1][2][7] - The company has strengthened its financial position and is on track to initiate Phase 2/3 clinical trials for SIL204 in the first half of 2026 [1][4][5] Recent Milestones & Business Highlights - The preclinical data for SIL204 shows up to 94% inhibition in pancreatic cancer cells with KRAS G12D mutations, approximately 90% inhibition in colorectal cancer cells, and significant dose-dependent inhibition in lung cancer cell lines [9] - A strategic partnership with Catalent was established for formulation development and clinical manufacturing of SIL204, supporting a dual-route development strategy [3] Regulatory and Clinical Timeline - Silexion plans to submit regulatory applications to initiate Phase 2/3 trials to the Israel Ministry of Health in Q4 2025 and to the European Union in Q1 2026 [4] Financial Overview - As of June 30, 2025, cash and cash equivalents increased to $3.5 million from $1.2 million at the end of 2024, reflecting successful financing activities [10] - Total operating expenses for Q2 2025 were $2.3 million, a 64.3% increase from Q2 2024, with R&D expenses rising to $1.0 million [11] - The net loss for Q2 2025 was $2.5 million, compared to $1.5 million in Q2 2024, primarily due to increased general and administrative expenses [13]
Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update